SOD1 and amyotrophic lateral sclerosis: Thus, these observations suggest that anti-RGMa antibody therapy effectively inhibited neurodegenerative processes in animal models of ALS and possesses therapeutic potential for treating patients with ALS by reducing SOD1 and ubiquitin aggregation.